Table 2.

Clinical characteristics of hypertensive patients.

Characteristics	Controlled hypertension		Uncontrolled hypertension		Total		p
	n	%	n	%	n	%
Comorbidities
Cardiac diseases	39	63.9	22	36.1	61	27.7	0.41
Stroke	5	71.4	2	28.6	7	3.2	0.52
Cerebrovascular diseases	7	70.0	3	30.0	10	4.6	0.49
Vascular diseases	19	76.0	6	24.0	25	11.4	0.08
Kidney diseases/failure	9	52.9	8	47.1	17	7.7	0.56
Metabolic syndrome	12	38.7	19	61.3	31	14.1	0.01
Blood lipid disorders	56	62.2	34	37.8	90	40.9	0.50
Digestive diseases	28	77.8	8	22.2	36	16.4	0.02
Diabetes	26	53.1	23	46.9	49	22.3	0.29
Cancer	1	50.0	1	50.0	2	0.9	0.78
Spine/joint pain	57	64.0	32	36.0	89	40.5	0.26
Liver diseases	9	40.9	13	59.1	22	10.0	0.06
Prostate diseases	7	70.0	3	30.0	10	4.6	0.49
Vestibular diseases	5	83.3	1	16.7	6	2.7	0.23
Duration of disease (years)
1– < 2 years	29	56.9	22	43.1	51	23.2	0.50
2–5 years	42	65.6	22	34.4	64	29.1
>5 years	60	57.1	45	42.9	105	47.7
Number of antihypertensive drugs used
1	21	61.8	13	38.2	34	15.5	0.77
≥2	110	59.1	76	40.9	186	84.6
Overweight/obesity
No	59	64.8	32	35.2	91	41.4	0.18
Yes	72	55.8	57	44.2	129	58.6
	Median	IQR	Median	IQR	Median	IQR	p
Duration of disease (years)	5	[3–10]	6	[2.2–10]	5	[3–10]	0.56
Number of comorbidities	2	[1–3]	2	[1–3]	2	[1–3]	0.72
Body mass index (kg/m2)	23.4	[21.8–25.2]	24.0	[22.3–26.1]	23.7	[21.9–25.4]	0.02
Last low-density lipoprotein (LDL, mmol/L)	2.5	[1.4–3.3]	2.3	[1.3–3.2]	2.5	[1.4–3.3]	0.67
Last high-density lipoprotein (HDL, mmol/L)	1.3	[1.1–1.6]	1.2	[1.1–1.4]	1.2	[1.1–1.6]	0.18
Last triglyceride (mmol/L)	1.8	[1.4–2.4]	2.0	[1.3–2.9]	1.9	[1.4–2.8]	0.35